Vrije Universiteit Brussel

Jette 10 trials 1 recruiting

10 Registered trials

1 Currently recruiting

Organisation

Vrije Universiteit Brussel

Location

Jette, Belgium

Identifier

ORG-100029074

Address

Pleinlaan 2, 1050, Belgium

Departments

Consultation Urology
Diabetes Research Center
Gerontology department (GERO)
Hematology
Human physiology and sports physiotherapy
Infectious Diseases
Medical Oncology
Neurology
Rheumatology

Clinical trials at this site (10)

Search interface

SARA-31: A phase 3 trial to evaluate the efficacy and safety of BIO-101 in elderly patients suffering from severe SARcopeniA: an interventio… Pending

2022-502417-28-01 Sarcopenia 5
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting

2024-518568-11-00 Hematological malignancies confirmed histologically: - 4 2019-02-04
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended

2023-508962-14-00 Relapsed/Refractory Multiple Myeloma 5 2020-06-18
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended

2023-510298-33-00 Prostate Cancer 4 2016-11-29
The role of brain neurotransmission in fatigue Ended

2024-514038-19-00 None 11 2025-09-15
A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes me… Ended

2023-506545-27-01 Diabetes mellitus, Type 1 4 2025-01-28
SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-… Ended

2022-500389-84-00 Febrile neutropenia 6 2024-02-16
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended

2022-500652-37-00 Advanced melanoma refractory to prior checkpoint inhibi 4 2022-12-01
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol… Ended

2023-510189-28-00 Rheumatoid Arthritis 6 2018-05-15